Clearmind Historical Balance Sheet

CMND Stock

USD 1.33 0.10 6.99%

Trend analysis of Clearmind Medicine Common balance sheet accounts such as Total Current Liabilities of 4.4 M, Total Stockholder Equity of 1.6 M or Accounts Payable of 541.2 K provides information on Clearmind Medicine's total assets, liabilities, and equity, which is the actual value of Clearmind Medicine Common to its prevalent stockholders. By breaking down trends over time using Clearmind Medicine balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Clearmind Medicine Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Clearmind Medicine Common is a good buy for the upcoming year.

Clearmind Medicine Inventory

(10,767.42)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Clearmind Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Clearmind Medicine Common at a specified time, usually calculated after every quarter, six months, or one year. Clearmind Medicine Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Clearmind Medicine and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Clearmind currently owns. An asset can also be divided into two categories, current and non-current.

Clearmind Medicine Balance Sheet Chart

At present, Clearmind Medicine's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 1.6 M, whereas Retained Earnings are projected to grow to (11.7 M).

Total Assets Total Current Liabilities Accounts Payable Other Current Assets

Total Assets

Total assets refers to the total amount of Clearmind Medicine assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Clearmind Medicine Common books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Clearmind Medicine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Clearmind Medicine Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Clearmind Medicine obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Clearmind Medicine Common are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Clearmind Medicine's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Clearmind Medicine Common current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	2.6M	3.6M	4.2M	4.4M
Total Assets	1.1M	4.3M	5.0M	5.2M

Total Current Liabilities Total Assets

Clearmind Medicine balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Common Stock Shares Outstanding	Other Stockholder Equity	Property Plant Equipment	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.79	0.77	-0.04	-0.77	0.6	0.99	0.78	0.79	0.32	1.0	0.32	0.92	0.79	-0.35	-0.98	0.36	1.0	0.93	0.04	0.84	0.87	-0.73	0.62	0.91	0.61
Total Current Liabilities	0.79		0.22	-0.62	-0.95	0.81	0.76	0.43	1.0	0.28	0.78	0.3	0.96	0.99	-0.35	-0.69	0.45	0.78	0.94	0.24	0.95	0.77	-0.55	0.02	0.97	0.0
Total Stockholder Equity	0.77	0.22		0.57	-0.22	0.07	0.8	0.76	0.22	0.21	0.78	0.19	0.46	0.23	-0.21	-0.85	0.05	0.78	0.5	-0.26	0.37	0.55	-0.57	0.97	0.44	0.97
Net Tangible Assets	-0.04	-0.62	0.57		0.51	-0.42	-0.02	0.39	-0.62	-0.02	-0.03	-0.07	-0.37	-0.65	0.13	-0.09	-0.11	-0.04	-0.32	-0.13	-0.55	-0.09	-0.08	0.73	-0.44	0.72
Retained Earnings	-0.77	-0.95	-0.22	0.51		-0.93	-0.72	-0.58	-0.95	-0.34	-0.74	-0.32	-0.95	-0.9	0.29	0.68	-0.64	-0.74	-0.94	-0.48	-0.83	-0.88	0.65	-0.05	-0.92	-0.01
Accounts Payable	0.6	0.81	0.07	-0.42	-0.93		0.52	0.61	0.81	0.3	0.56	0.28	0.82	0.72	-0.22	-0.48	0.82	0.55	0.83	0.76	0.6	0.83	-0.61	-0.06	0.76	-0.11
Cash	0.99	0.76	0.8	-0.02	-0.72	0.52		0.74	0.76	0.29	1.0	0.3	0.89	0.77	-0.38	-0.98	0.26	1.0	0.9	-0.07	0.84	0.82	-0.69	0.65	0.89	0.64
Other Current Assets	0.78	0.43	0.76	0.39	-0.58	0.61	0.74		0.43	0.29	0.76	0.24	0.66	0.35	-0.27	-0.79	0.57	0.75	0.71	0.42	0.36	0.85	-0.73	0.72	0.57	0.68
Total Liab	0.79	1.0	0.22	-0.62	-0.95	0.81	0.76	0.43		0.28	0.78	0.3	0.96	0.99	-0.35	-0.69	0.45	0.78	0.94	0.24	0.95	0.77	-0.55	0.02	0.97	0.0
Short Long Term Debt	0.32	0.28	0.21	-0.02	-0.34	0.3	0.29	0.29	0.28		0.3	0.97	0.33	0.25	0.27	-0.3	0.37	0.29	0.33	0.17	0.24	0.43	-0.42	0.16	0.3	0.15
Total Current Assets	1.0	0.78	0.78	-0.03	-0.74	0.56	1.0	0.76	0.78	0.3		0.31	0.91	0.78	-0.38	-0.98	0.3	1.0	0.92	-0.02	0.84	0.84	-0.7	0.64	0.9	0.62
Short Term Debt	0.32	0.3	0.19	-0.07	-0.32	0.28	0.3	0.24	0.3	0.97	0.31		0.33	0.28	0.16	-0.29	0.29	0.3	0.33	0.11	0.28	0.37	-0.35	0.13	0.32	0.12
Common Stock	0.92	0.96	0.46	-0.37	-0.95	0.82	0.89	0.66	0.96	0.33	0.91	0.33		0.93	-0.35	-0.84	0.53	0.9	1.0	0.27	0.92	0.9	-0.7	0.28	0.99	0.26
Other Current Liab	0.79	0.99	0.23	-0.65	-0.9	0.72	0.77	0.35	0.99	0.25	0.78	0.28	0.93		-0.37	-0.69	0.34	0.78	0.91	0.11	0.98	0.71	-0.49	0.02	0.97	0.01
Property Plant And Equipment Net	-0.35	-0.35	-0.21	0.13	0.29	-0.22	-0.38	-0.27	-0.35	0.27	-0.38	0.16	-0.35	-0.37		0.39	0.31	-0.4	-0.36	0.06	-0.37	-0.3	-0.03	-0.18	-0.38	-0.18
Net Debt	-0.98	-0.69	-0.85	-0.09	0.68	-0.48	-0.98	-0.79	-0.69	-0.3	-0.98	-0.29	-0.84	-0.69	0.39		-0.24	-0.98	-0.86	0.06	-0.77	-0.83	0.7	-0.73	-0.83	-0.72
Non Current Assets Total	0.36	0.45	0.05	-0.11	-0.64	0.82	0.26	0.57	0.45	0.37	0.3	0.29	0.53	0.34	0.31	-0.24		0.28	0.54	0.84	0.22	0.62	-0.61	-0.03	0.42	-0.09
Cash And Short Term Investments	1.0	0.78	0.78	-0.04	-0.74	0.55	1.0	0.75	0.78	0.29	1.0	0.3	0.9	0.78	-0.4	-0.98	0.28		0.91	-0.04	0.85	0.83	-0.69	0.64	0.9	0.63
Net Receivables	0.93	0.94	0.5	-0.32	-0.94	0.83	0.9	0.71	0.94	0.33	0.92	0.33	1.0	0.91	-0.36	-0.86	0.54	0.91		0.29	0.9	0.91	-0.7	0.32	0.98	0.29
Non Current Liabilities Total	0.04	0.24	-0.26	-0.13	-0.48	0.76	-0.07	0.42	0.24	0.17	-0.02	0.11	0.27	0.11	0.06	0.06	0.84	-0.04	0.29		-0.06	0.45	-0.33	-0.26	0.15	-0.33
Common Stock Shares Outstanding	0.84	0.95	0.37	-0.55	-0.83	0.6	0.84	0.36	0.95	0.24	0.84	0.28	0.92	0.98	-0.37	-0.77	0.22	0.85	0.9	-0.06		0.68	-0.5	0.16	0.96	0.16
Other Stockholder Equity	0.87	0.77	0.55	-0.09	-0.88	0.83	0.82	0.85	0.77	0.43	0.84	0.37	0.9	0.71	-0.3	-0.83	0.62	0.83	0.91	0.45	0.68		-0.8	0.43	0.84	0.4
Property Plant Equipment	-0.73	-0.55	-0.57	-0.08	0.65	-0.61	-0.69	-0.73	-0.55	-0.42	-0.7	-0.35	-0.7	-0.49	-0.03	0.7	-0.61	-0.69	-0.7	-0.33	-0.5	-0.8		-0.49	-0.64	-0.45
Net Invested Capital	0.62	0.02	0.97	0.73	-0.05	-0.06	0.65	0.72	0.02	0.16	0.64	0.13	0.28	0.02	-0.18	-0.73	-0.03	0.64	0.32	-0.26	0.16	0.43	-0.49		0.25	1.0
Capital Stock	0.91	0.97	0.44	-0.44	-0.92	0.76	0.89	0.57	0.97	0.3	0.9	0.32	0.99	0.97	-0.38	-0.83	0.42	0.9	0.98	0.15	0.96	0.84	-0.64	0.25		0.23
Net Working Capital	0.61	0.0	0.97	0.72	-0.01	-0.11	0.64	0.68	0.0	0.15	0.62	0.12	0.26	0.01	-0.18	-0.72	-0.09	0.63	0.29	-0.33	0.16	0.4	-0.45	1.0	0.23

Click cells to compare fundamentals

Clearmind Medicine Account Relationship Matchups

Clearmind Medicine balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	512.7K	5.2M	1.1M	4.3M	5.0M	5.2M
Total Current Liabilities	13.4K	357.2K	2.6M	3.6M	4.2M	4.4M
Total Stockholder Equity	499.3K	4.8M	(1.5M)	1.4M	1.6M	1.6M
Net Tangible Assets	133.8K	319.6K	4.6M	(1.7M)	(1.9M)	(1.8M)
Retained Earnings	(539.7K)	(4.4M)	(13.8M)	(13.6M)	(12.3M)	(11.7M)
Accounts Payable	4.0K	281.5K	1.0M	448.2K	515.4K	541.2K
Cash	329.8K	4.6M	175.8K	3.9M	4.5M	4.7M
Total Liab	13.4K	357.2K	2.6M	3.6M	4.2M	4.4M
Total Current Assets	333.0K	4.9M	593.3K	4.2M	4.8M	5.1M
Common Stock	891.7K	7.9M	9.2M	12.4M	14.3M	15.0M
Other Current Liab	6.1K	6.7K	1.6M	3.2M	3.6M	3.8M
Property Plant And Equipment Net	179.7K	20.6K	66.4K	1.2K	1.1K	1.1K
Net Debt	(329.8K)	(4.6M)	(123.4K)	(3.9M)	(3.5M)	(3.4M)
Non Current Assets Total	179.7K	238.6K	534.7K	115.3K	132.6K	224.1K
Cash And Short Term Investments	329.8K	4.6M	440.2K	4.0M	4.6M	4.8M
Net Receivables	3.1K	129.8K	133.7K	174.6K	200.8K	210.8K
Liabilities And Stockholders Equity	512.7K	5.2M	1.1M	4.3M	5.0M	5.2M
Non Current Liabilities Total	7.6K	12.7K	5.3K	348.9K	2.0M	0.0
Common Stock Shares Outstanding	18.1K	30.9K	43.3K	202.5K	232.9K	244.5K
Other Stockholder Equity	369.7K	2.9M	2.5M	2.6M	3.0M	1.6M
Net Invested Capital	499.3K	4.8M	(1.5M)	983.5K	885.1K	785.4K
Capital Stock	891.7K	7.9M	9.2M	17.1M	19.7M	20.7M
Net Working Capital	319.6K	4.6M	(2.0M)	824.8K	742.3K	579.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:

How To Invest In Clearmind

Details

Is Clearmind Stock a good investment?

Details

What is Clearmind Medicine's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.23)

Return On Assets

(0.58)

Return On Equity

(2.68)

The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Clearmind Historical Balance Sheet

Clearmind Medicine Inventory

(10,767.42)

About Clearmind Balance Sheet Analysis

Clearmind Medicine Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Other Current Assets

Clearmind Medicine balance sheet Correlations

Clearmind Medicine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Clearmind Medicine balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Total Current Assets

Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets
Net Debt	- 0.98	Cash
Net Debt	- 0.98	Total Assets
Common Stock	- 0.95	Retained Earnings
Total Liab	- 0.95	Retained Earnings